Industry can play role in educating consumers about new drugs' risks and benefits

09/27/2011

Results of a recent study show that consumers generally prefer new drugs over older drugs, without fully understanding the newer drugs' risks and benefits. These findings demonstrate that the FDA's efforts to inform the public about its approval process are insufficient. "This study confirms that the public lacks understanding of what FDA approval constitutes," pharma industry consultant Wayne Pines noted. Industry can play a role in consumer education as well, according to Peter Pitts, president and co-founder of the Center for Medicine in the Public Interest. Read more.

View Full Article in:

http://www.cohealthcom.org/2011/09/21/gaps-in-public-understanding-of-new-drugs-...

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC